Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Lara P, Tangen C, Heath E, Gulati S, Stein M, Meng M, Alva A, Pal S, Puzanov I, Clark J, Choueiri T, Agarwal N, Uzzo R, Haas N, Synold T, Plets M, Vaishampayan U, Shuch B, Lerner S, Thompson I, Ryan C. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. European Urology 2024, 86: 258-264. PMID: 38811313, DOI: 10.1016/j.eururo.2024.05.012.Peer-Reviewed Original ResearchRecurrence-free survivalHigh-risk diseaseRenal cell cancerPhase 3 trialOverall survivalEverolimus armCell histologyPlacebo armDiscontinuation rate due to adverse eventsHigh-risk renal cell carcinomaCompare recurrence-free survivalPatients treated with everolimusPositive phase 3 trialClear cell renal cell cancerCell renal cell cancerRate of side effectsClear cell histologyComparison to placeboComplete surgical removalNode-positive statusRisk of recurrenceRisk stratification toolCox regression modelsAdjuvant sunitinibAdjuvant trials